Member Info for dafad

yes

try this link and click on where it says click here

https://www.regenhealthsolutions.info/2020/11/14/treatments-for-people-with-early-covid-19-infection-is-an-urgent-research-focus-according-to-a-jama-viewpoint-article-by-niaid-director-anthony-s-fauci-m-d-and-colleagues/

Sng from 14.10

an appropriate application of Interferons through the nose or whatever
Watch here from 2.17

https://www.youtube.com/watch?v=IqhGF4JLaTM

mote Monitored Systems plc ("RMS" or the "Company")

Pharm 2 Farm Update

The Company is pleased to issue the following update on its wholly owned subsidiary Pharm 2Farm Limited ("P2F").

P2F is continuing to receive enquiries from prospective distributors and purchasers for its viricidal mask and now anticipates that future demand for its mask may outstrip the production line capacity of five million viricidal face masks per month.

To fulfil part of the anticipated excess demand, P2F expects to supply its patented filter material, initially, to certain partner mask manufacturers, until P2F has itself procured additional production lines.

Over the weekend P2F signed binding heads of terms with a manufacturer of surgical masks in Germany. The German manufacturer will subcontract to supply complete masks to P2F to the P2F specification and brand name, and also purchase P2F filter material for their own brand masks. Under the heads of terms the manufacturer will also develop and supply anti-viral C-Fold masks using P2F filter material to extend P2F's market reach. The heads of terms are subject to final contractual agreement between the parties.

The Company will provide further updates to the market as appropriate.

ENDS

ENQUIRIES:

Boom

I totally agree that passangers are supposed to wear face masks ,but what is considered to be a mask,they come in
all shapes and sizes but more importantly how many are up to stanard and have passed the stringiest tests?Surely if all pasangers had to wear a standard safety/health approved mask for the duration of the flight it would give everyone on the plane a sense of safety.A£1 pound levy for the mask would not break the bank for most passangers

In 2018 there were4.4 billion airline passangers,now just imagine if we managed to get a tenth of that market just for starters.Getting each airline cos to supply the mask on checking in.not impossible

This explains the wearer and those in close proximity

Scientists develop facemask which can kill viruses on contact

A new antiviral facemask which uses nanotechnology to kill viruses including COVID-19 and influenza has been designed and developed by a Nottingham Trent University scientist. Instead of the usual three-ply design, the five-ply surgical mask includes an additional antiviral inner layer which incorporates nano-copper created using a patented process developed at the university. The copper, which is embedded into the mask material, has ions that are emitted once in contact with a virus and this then creates an interaction with the virus's genetic material causing it to die and stop reproducing. Because they are spherical, nanoparticles have a large surface area making the approach more effective at killing the virus. The antiviral inner layer ensures additional protection for both the wearer and those in proximity.

The mask has been designed by Nottingham Trent University scientist and nanotechnology expert, Dr Gareth Cave, and is now being commercialised by NTU spin out company Pharm2Farm in Nottingham's BioCity.

The company, which was founded by Dr Cave, uses a patented process to produce and functionalise nanoparticles for a range of human, crop and animal health benefits. Tests showed that the masks, which are Type IIR - meaning they offer the highest level of protection and have a filtration efficiency of 99.98% - were highly effective, at killing more than 90% of the influenza and coronavirus over seven hours, and have been certified to ISO 18184 standards. The masks include a fluid-repellent layer on the outside - to reduce inhalation of droplets of saliva and mucus that carry COVID-19 - the antiviral nanotech layer between two filter layers, and a hypoallergenic breathable innermost layer.While current conventional surgical masks block the virus, it can remain on or in the mask while being worn and after it has been disposed of.

The masks are expected to go into production in Nottingham later this month and will be commercially available from December for healthcare, transport and food service settings initially.Despite the additional layer and the antiviral properties, the masks will be in line with current Type IIR mask prices.

to keep momentum

Last time when Sng gave out good news the press concentrated on vaccine news which was out on the same day
lets hope that Cummings leaving does not take up our front page space today

If the Lancet article does show up tonight ,it probably means that RM was aware of this and thus the silence from the
co during the last few days

He didnt seem to confident!!

and thats is if they get approval
Tweet
See new Tweets
Conversation
SkyNews
@SkyNews
#COVID19: Ugur Sahin, co-founder of BioNTech, says things will get worse before they get better, but the vaccine may be available by Christmas in the UK.

Read more here: https://trib.al/p1vMI0w

ThIS was published yesterday

Furthermore, the inhaled IFN-ß-1a reduced the risk of developing severe COVID-19 among 101 patients by 79 % in phase 2 clinical trial (NCT04385095) in the United Kingdom [79].

Concluding remarks
More effective COVID-19 patient management protocols to ensure the reduced need for prolonged mechanical ventilation, short hospital stays, and to reduce the morbidity and mortality associated with COVID-19 are still lacking. Despite the controversial results of CQ/HCQ and AZM in the treatment of COVID-19 in recent days, several countries continue to allow their use in the treatment of COVID-19 patients. However, the use of CQ/HCQ and AZM should remain restrained because the results of new studies do not validate these treatments in the management of COVID-19. Nevertheless, in the situation of a supposed bacterial super-infection that can complicate the COVID-19, clinicians may wish to prescribe AZM. The lung injury in COVID-19 patients is associated with ROS release by phagocytes, and thus the use of antioxidants is necessary for the management of COVID-19. Besides, type I and type III IFNs have shown antiviral activities both in vitro and in vivo. Type I IFN was effective in treating COVID-19 patients than other forms of treatment without IFN; thus, we hypothesize that the use of type I and III IFNs in the early stage of COVID-19 combined with an adapted antioxidant and anti-inflammatory drug in the advanced stage could help improve the clinical outcomes. The vaccine remains an efficient agent for COVID-19 protection, and the preliminary reports of the candidate vaccines showcase some encouraging results.

https://www.sciencedirect.com/science/article/pii/S0753332220312002#sec0025

Article was tweeted by Rockerfeller Uni

https://knowablemagazine.org/article/health-disease/2020/genetic-susceptibility-to-coronavirus-covid-19

of announcment

comhttps://www.axios./pfizer-ceo-albert-bourla-stock-sale-covid-vaccine-c380a500-ee02-4106-befe-88b08c656d39.html?utm_source=twitter&utm_medium=social&utm_campaign=organic&utm_content=1100

applies here as well

S Number : 8922E

Evgen Pharma PLC

11 November 2020

Evgen Pharma plc

("Evgen" or the "Company")

Comment on COVID-19 vaccine announcement

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, notes the recent news that Pfizer have announced the first interim analysis of a Phase III COVID-19 vaccine. Evgen believe that multiple approaches will be needed to curtail this virus and the progress announced earlier this week is a hugely positive development.

As previously announced, Evgen have entered into a Phase II/III trial with the University of Dundee to investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") including, but not exclusively in patients with suspected COVID-19. The Company confirms that this study is poised to commence recruitment, as announced on 23 October 2020 and will be providing a further update shortly.

The Phase II/III STAR trial (SFX-01 Treatment for Acute Respiratory Infections) has received all the necessary regulatory approvals needed to proceed and patient recruitment will begin shortly. Supplies of SFX-01 have already been delivered to the centre.

Dr Huw Jones, Evgen CEO, commented: "We are pleased to see such progress on a potential vaccine against COVID-19. Recently ARDS has been heavily associated with COVID-19 as it affects the respiratory tract, but it is and will remain a condition in its own right long after we have beaten the pandemic and will continue to be a huge problem for patients. There is a considerable unmet need for effective treatments for ARDS and the outcome of our study will hopefully show how we can use SFX-01 in a serious respiratory condition regardless of the infective agent involved."

https://www.bmj.com/content/371/bmj.m4037